Evidence map›Paper›PMID 38954072›Full record

ArticleMolecular diversity2024

Identification of potential PIM-2 inhibitors via ligand-based generative models, molecular docking and molecular dynamics simulations.

Tianli Qin, Yijian Wang, Miaomiao Kong, Hongliang Zhong, Tao Wu, Zixuan Xi, Zhenyong Qian, Ke Li, Yuepiao Cai, Jianzhang Wu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tianli QinThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Yijian WangThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Miaomiao KongThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Hongliang ZhongThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Tao WuThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Zixuan XiThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Zhenyong QianThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Ke LiThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Yuepiao CaiSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325000, China. ypcai@wmu.edu.cn.
Jianzhang WuThe Eye Hospital, School of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, 325027, China. wjzwzmu@163.com.
Wulan LiThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. lwlwzmu@163.com.

Funding

Research Initiation Project of the Eye Hospital, School of Ophthalmology & Optometry, Wenzhou Medical University KYQD20230901Science and Technology Department of National Administration of Traditional Chinese Medicine & Zhejiang Provincial Administration of Traditional Chinese Medicine GZY-ZJ-KJ-23032ZheJiang Province Natural Science Funding of China LGF20B020001
6 · The paper itself

Abstract

Proviral Integrations of Moloney-2 (PIM-2) kinase is a promising target for various cancers and other diseases, and its inhibitors hold potential for treating related diseases. However, there is currently no clinically available PIM-2 inhibitor. In this study, we constructed a generative model for de novo PIM-2 inhibitor design based on artificial intelligence, performed molecular docking and molecular dynamics (MD) simulations to develop an efficient PIM-2 inhibitor generative model and discover potential PIM-2 inhibitors. First, we designed a generative model based on a Bi-directional Long Short-Term Memory (BiLSTM) framework combined with a transfer learning strategy and generated a new PIM-2 small molecule library using existing active drug databases. The generated compound library was then virtually screened by molecular docking and scaffold similarity comparison, identifying 10 initial hit compounds with better performance. Next, using the inhibitor in the crystal structure as a positive control, we performed two rounds of MD simulations, with lengths of 100 ns and 500 ns, respectively, to study the dynamic stability of the protein-ligand systems of the 10 compounds with PIM-2. Analyzed the interactions with key hinge region residues, binding free energies, and changes in the ATP pocket size. The generative model demonstrates good molecular generation capability and can generate efficient novel molecules with similar physicochemical properties as active PIM-2 drugs. Among the 10 initially selected hit compounds, 5 compounds C3 (- 29.69 kcal/mol), C4 (- 33.31 kcal/mol), C5 (- 28.59 kcal/mol), C8 (- 34.68 kcal/mol), and C9 (- 25.88 kcal/mol) have higher binding energies with PIM-2 than the positive drug 3YR (- 26.18 kcal/mol). The MD simulation results are consistent with the docking analysis, these compounds have lower and more stable RMSD values for the complex systems with the reported positive drug 3YR and PIM-2 complex system. They can form long-term stable interactions with active site and the hinge region of PIM-2, which suggests these compounds are likely to have potent inhibitory effects on PIM-2. This study provides an efficient generative model for PIM-2 inhibitor research and discovers 5 potential novel PIM-2 inhibitors.

Indexed as

Molecular Docking SimulationMolecular Dynamics SimulationProtein Kinase InhibitorsDrug DesignHumansLigandsProtein BindingProtein Serine-Threonine KinasesProto-Oncogene ProteinsSmall Molecule LibrariesLigandsPIM2 protein, humanProtein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene ProteinsSmall Molecule LibrariesDe novo drug generationDrug discoveryMolecular dynamicsProviral Integrations of Moloney-2

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.